Over the past several decades, there has been increasing awareness of and focus on the nonmotor aspects of Parkinson's disease (PD). These include disordered autonomic function, cognitive impairment, and neuropsychiatric features including depression, anxiety, and psychosis. Neuropsychiatric symptoms are common, contribute to PD-related disability, and negatively impact health-related quality of life. In spite of the increasing awareness, these symptoms may still go unrecognized and under-treated due to an inappropriate singular focus on motor symptoms. Compounding this, the current evidence base is insufficient to guide appropriate treatment of psychiatric symptoms in PD. Treatment approaches often reflect those used in the general population, which may not be appropriate given suspected differences in mechanisms. A better understanding of the underlying pathophysiology may inform approaches toward treatment.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to The American Journal of Geriatric Psychiatry
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Brainstem pathologies correlate with depression and psychosis in Parkinson's disease.Am J Geriatr Psychiatry. 2021; 29: 958-968https://doi.org/10.1016/j.jagp.2020.12.009
- Depression rating scales in Parkinson's disease: critique and recommendations.Mov Disord. 2007; 22: 1077-1092
- A randomized, double-bling, placebo-controlled trial of antidepressants in Parkinson disease.Neurology. 2012; 78: 1229-1236
- The psychosis spectrum in Parkinson disease.Nat Rev Neurol. 2017; 13: 81-95
- Report from a multidisciplinary meeting on anxiety as a non-motor manifestation of Parkinson's disease.NPJ Parkinsons Dis. 2019; 5: 30
- Anxiety rating scales in Parkinson's disease: a validation study of the Hamilton anxiety rating scale, the Beck anxiety inventory, and the hospital anxiety and depression scale.Mov Disord. 2011; 26: 407-415
- The Parkinson Anxiety Scale (PAS): development and validation of a new anxiety scale.Mov Disord. 2014; 29: 1035-1043
- A trial of buspirone for anxiety in Parkinson's disease: safety and tolerability.Parkinsonism Relat Disord. 2020; 81: 69-74
Published online: January 18, 2021
Accepted: January 12, 2021
Received: January 11, 2021
© 2021 American Association for Geriatric Psychiatry. Published by Elsevier Inc. All rights reserved.